Wikipedia

Moein Moghimi

Moein Moghimi is a British professor and researcher in the fields of nanomedicine, drug delivery and biomaterials. He is currently the professor of Pharmaceutics and Nanomedicine at the School of Pharmacy and the Translational and Clinical Research Institute at Newcastle University. He is also an adjoint professor at the Skaggs School of Pharmacy, University of Colorado Denver.

Moein Moghimi
NationalityBritish
Academic background
Alma mater
University of Manchester (BSc)
Academic work
DisciplineBiochemistry, nanotechnology
Sub-disciplineDrug delivery
Nanomedicine
Nanosafety
Innate immunity and complement system
Pharmaceutical nanotechnology
Pharmaceutical sciences
InstitutionsNewcastle University

He is known for his fundamental and translational research in nanomedicine and drug delivery, especially in polymeric and nanomaterials' cell and immune safety, and as an inventor of nanosystems for tissue-specific targeting.

Moghimi's publications in nanomedicine are widely cited. A study conducted by Stanford University listed Moghimi among the top 0.1% of world’s leading scientists across in all fields.[1] He founded the Centre for Pharmaceutical Nanotechnology and Nanotoxicology (CPNN) at University of Copenhagen and was its director until 2016. He co-founded S. M. Discovery Group which develops products based on his inventions.[2] He is currently editor-in-chief of the Journal of Nanotheranostics.

Early life and education edit

Moghimi completed his secondary education at D'Overbroeck's College in Oxford, United Kingdom. He pursued a bachelor's degree in biochemistry at the University of Manchester and graduated with honors in 1985. He completed his PhD in liposome immunobiology/biochemistry in 1989 at the Biochemistry Department of the Charing Cross Hospital Medical School at Imperial College London (then University of London) under the mentorship of Harish M. Patel.[3]

He then joined Stanley Stewart Davis' laboratory at the Department of Pharmaceutical Sciences, University of Nottingham for postdoctoral training in advanced drug delivery system engineering. Later he became a University Research Fellow at University of Nottingham.

Academic career edit

Moghimi was the senior lecturer of Biopharmacy and Molecular Pharmaceutics at the School of Pharmacy, University of Brighton from 1998 until 2008. From 2008 until 2010, he was honorary professor of nanomedicine at the Multidisciplinary Research Center, Shantou University.[4]

He was also a full affiliate professor at the Methodist Research Institute, Houston Methodist Hospital systems in Texas between 2013 and 2017.[5] In 2015, he was a visiting professor at Università degli Studi di Padova.[6]

From 2008 until 2016,[4] he was professor of nanomedicine in the department of pharmacy and professor of pharmaceutical nanotechnology at the Nanoscience Center,[7][8] as well as the founder and director of the Centre for Pharmaceutical Nanotechnology and Nanotoxiocology at the University of Copenhagen.[9][10]

Prior to 2017, Moghimi was professor and chair in pharmaceutics at the Durham University School of Medicine, Pharmacy and Health. Since 2017, he has been professor of Pharmaceutics and Nanomedicine at the School of Pharmacy and Translational and Clinical Research Institute, both part of Newcastle University. He is adjoint professor at the department of pharmaceutical sciences at Skaggs School of Pharmacy, University of Colorado Denver Medical Center.[4]

Editorial activities edit

Moghimi is editor-in-chief of the Journal of Nanotheranostics.[11] He is associate editor of Molecular Therapy[12] and Drug Delivery,[13] and serves on the editorial boards of journals such as Advanced Drug Delivery Reviews,[14] Journal of Controlled Release,[15] and Nanomedicine-UK.[5]

Research edit

Moghimi is known for his work in nanoparticle engineering for biomedical applications, nanosafety, and mechanistic understanding of nanoparticle-mediated complement activation. His research focuses on interdisciplinary approaches to nanotherapies.[16][17] Much of his research is related to the management and treatment of chronic conditions associated with population ageing including cancer,[18] neurological disorders such as Parkinson's disease and Alzheimer's disease, cardiovascular disease, allergies and arthritis.[6] He specializes in the design and surface engineering of nanosystems and nanoparticles for tissue-specific drug delivery and imaging.[7][19][20]

His current work includes the development of a concomitant long-term computational network assessment of genomics and epigenomic factors in inter-individual variations to nanomedicine performance and cell re-programming.[4]

Resulting from his PhD research, Moghimi introduced the opsonin-dysopsonin hypothesis, suggesting a regulatory role for certain blood proteins in limiting nanoparticle uptake by macrophages.[21] This hypothesis was later applied to highlight multifaceted mechanisms regulating the pharmacokinetic performance of long-circulating drug carriers.[22][23]

Moghimi has developed a range of injectable nanosystems, including an early prototype of splenotropic and lymphotropic nanoparticles based on the concept of steric stabilisation and surface engineering with block copolymers. These concepts are applied for splenic and lymphatic targeting with liposomes and polymeric nanospheres.[24][25]

A research group led by Moghimi developed NanoLigand Carriers,[26] induced self-assemblies of phage-derived display peptides that on intravenous injection rapidly target two receptors on the blood brain-barrier. On crossing the blood–brain barrier, the carriers target neurons and microglia and deliver their therapeutic nucleic acid payloads to cells. These peptides have applications for the treatment of neurodegenerative disorders.[27][28]

His laboratory was among the first to explain polycation-mediated cell death processes.[29][30] Moghimi's laboratory has contributed to the molecular understanding of nanomaterial interactions with elements of the innate immune system and translating these to design immune safe nanoparticles. His laboratory demonstrated the first in vivo assembly of long-circulating and splenotropic nanoparticles without prior surface modification or manipulation of macrophage function,[31] as well as the first demonstration of the detection of stealth nanoparticles by primed and activated immune cells.[32]

This research has involved mapping nanoparticle properties that trigger complement activation and, notably, the role of polymer conformation and hydration in switching complement activation pathways.[33] He has resolved some challenging mechanisms modulating complement activation by stealth and polymer-coated nanoparticles.[34] His research also explained the molecular basis of complement activation by polyethylene glycol, a polymer that is used widely for prolonging the blood circulation time of proteins and particulate drug carriers.[35][36]

His lab was the first to demonstrate tumour growth promotion by stealth nanoparticles through local nanoparticle-mediated complement activation,[37] and developed the first complement-evading hexosomes.[38]

He has challenged the validity of the CARPA (Complement Activation Related Pseudo-Allergy) hypothesis, and proposed a working mechanism explaining idiosyncratic nanomedicine-mediated anaphylaxis seen in patients.[39][40] Moghimi also introduced the nanomaterial projected "Angstrom-Scale Spacing Arrangement" hypothesis, in modulating complement system responses to nanomedicines and medical implants.[41]

In 2020, Moghimi commented on the sudden closure of the Centers of Cancer Nanotechnology Excellence in the United States, and called for support in curiosity driven research in fundamental nanomedicine even in the absence of immediate obvious benefits to society.[42]

Selected bibliography edit

  • "Nanomedicine: Shadow and substance". Handbook of Clinical Nanomedicine (2nd ed.). Pan Stanford Publishing. 2016. ISBN 9789814669221.. With Fahrangrazi, Shadi.
  • "Particle Nanoengineering for the Lymphatic System and Lymph Node Targeting". Polymer-Based Nanostructures: Medical Applications. RCS Nanoscience and Nanotechnology Series. Royal Society of Chemistry. 2010. ISBN 9780854049561.

Selected articles edit

External links edit

References edit

  1. ^ Jeroen Baas; Boyack, Kevin; Ioannidis, John P. A. (2021). ""Updated science-wide author databases of standardized citation indicators"". 3. Elsevier BV. doi:10.17632/btchxktzyw.3. {{cite journal}}: Cite journal requires |journal= (help)
  2. ^ "Leadership". SMDG.
  3. ^ "Invited speakers". CESPT 2023.
  4. ^ a b c d "Staff Profile School of Pharmacy Newcastle University". ncl.ac.uk.
  5. ^ a b "Nanomedicine Editorial Board". Nanomedicine.
  6. ^ a b "M. Moghimi". USERN.
  7. ^ a b "Nano-drugs are bad news for diseases". University Post. 30 November 2001.
  8. ^ "Meet Our Editorial Board Member: S. Moein Moghimi". ResearchGate.
  9. ^ "Nanotechnology Now - News Story: Denmark funds nanotechnology". nanotech-now.
  10. ^ "Donation for new Center for Pharmaceutical Nanotechnology and Nanotoxicology". EurekAlert!.
  11. ^ Moghimi, S. (December 2020). "The Journal of Nanotheranostics: A New Open-Access Journal at the Interface of Nanotechnology, Materials Science, and Medicine for Precision Medicine". Journal of Nanotheranostics. 1 (1): 56–57. doi:10.3390/jnt1010005. ISSN 2624-845X.
  12. ^ "Molecular Therapy editorial board contacts". Cell.com.
  13. ^ "Editorial board".
  14. ^ "Editorial board ADDR". sciencedirect.com.
  15. ^ "Editorial board - JCR". www.sciencedirect.com.
  16. ^ Moghimi, S. Moein; Hunter, A. Christy; Murray, J. Clifford (March 2005). "Nanomedicine: current status and future prospects". The FASEB Journal. 19 (3): 311–330. doi:10.1096/fj.04-2747rev. ISSN 0892-6638. PMID 15746175. S2CID 30173777.
  17. ^ Moghimi, Seyed M.; Simberg, Dmitri; Anchordoquy, Thomas J. (March 2020). "Tuning the Engines of Nanomedicine". Molecular Therapy. 28 (3): 693–694. doi:10.1016/j.ymthe.2020.01.025. PMC 7054826. PMID 32032534.
  18. ^ "Cancer gene therapy from camels". ScienceDaily.
  19. ^ "Plastic cubes injected into the body could replace booster shots". New Scientist.
  20. ^ "Study: How to keep nanoparticle caterpillars safe from the crows of the immune system". EurekAlert!.
  21. ^ Papini, E.; Tavano, R.; Mancin, F. (2020). "Opsonins and Dysopsonins of Nanoparticles: Facts, Concepts, and Methodological Guidelines". Frontiers in Immunology. 11: 567365. doi:10.3389/fimmu.2020.567365. PMC 7587406. PMID 33154748.
  22. ^ Moghimi, S.M; Patel, H.M (1998-06-08). "Serum-mediated recognition of liposomes by phagocytic cells of the reticuloendothelial system - The concept of tissue specificity". Advanced Drug Delivery Reviews. 32 (1–2): 45–60. doi:10.1016/S0169-409X(97)00131-2. PMID 10837635.
  23. ^ Moghimi, S. M.; Muir, I. S.; Illum, L.; Davis, S. S.; Kolb-Bachofen, V. (1993-11-07). "Coating particles with a block co-polymer (poloxamine-908) suppresses opsonization but permits the activity of dysopsonins in the serum". Biochimica et Biophysica Acta (BBA) - Molecular Cell Research. 1179 (2): 157–165. doi:10.1016/0167-4889(93)90137-e. PMID 8218358.
  24. ^ Moghimi, S.M.; Porter, C.J.H.; Muir, I.S.; Illum, L.; Davis, S.S. (1991-06-14). "Non-phagocytic uptake of intravenously injected microspheres in rat spleen: influence of particle size and hydrophilic coating". Biochemical and Biophysical Research Communications. 177 (2): 861–866. doi:10.1016/0006-291X(91)91869-E. PMID 2049107.
  25. ^ Moghimi, S. M.; Hawley, A. E.; Christy, N. M.; Gray, T.; Illum, L.; Davis, S. S. (1994-05-09). "Surface engineered nanospheres with enhanced drainage into lymphatics and uptake by macrophages of the regional lymph nodes". FEBS Letters. 344 (1): 25–30. doi:10.1016/0014-5793(94)00351-3. PMID 8181558. S2CID 31767077.
  26. ^ Wu, Lin-Ping; Ahmadvand, Davoud; Su, Junan; Hall, Arnaldur; Tan, Xiaolong; Farhangrazi, Z. Shadi; Moghimi, S. Moein (2019-10-11). "Crossing the blood-brain-barrier with nanoligand drug carriers self-assembled from a phage display peptide". Nature Communications. 10 (1): 4635. Bibcode:2019NatCo..10.4635W. doi:10.1038/s41467-019-12554-2. PMC 6789111. PMID 31604928.
  27. ^ "Realising The Potential of Nanomedicine - Formulation & Delivery Approaches". Oxford Global.
  28. ^ "Beyond the Barrier". The Medicine Maker. 2019-11-12.
  29. ^ "7 Molecular Therapy classics to read for ASGCT 2017". crosstalk.cell.com.
  30. ^ Moghimi, S. M.; Symonds, P.; Murray, J. C.; Hunter, A. C.; Debska, G.; Szewczyk, A. (June 2006). "A two-stage poly(ethylenimine)-mediated cytotoxicity: implications for gene transfer/therapy". Molecular Therapy: The Journal of the American Society of Gene Therapy. 11 (6): 990–995. doi:10.1016/j.ymthe.2005.02.010. PMID 15922971.
  31. ^ Moghimi, S. M. (1997-07-19). "Prolonging the circulation time and modifying the body distribution of intravenously injected polystyrene nanospheres by prior intravenous administration of poloxamine-908. A 'hepatic-blockade' event or manipulation of nanosphere surface in vivo?". Biochimica et Biophysica Acta (BBA) - General Subjects. 1336 (1): 1–6. doi:10.1016/s0304-4165(97)00060-3. PMID 9271243.
  32. ^ Moghimi, S. M.; Hedeman, H.; Christy, N. M.; Illum, L.; Davis, S. S. (1993). "Enhanced hepatic clearance of intravenously administered sterically stabilized microspheres in zymosan-stimulated rats". Journal of Leukocyte Biology. 54 (6): 513–517. doi:10.1002/jlb.54.6.513. PMID 8245702. S2CID 42780562.
  33. ^ Sim, R. B.; Wallis, R. (February 2011). "Immune attack on nanoparticles". Nature Nanotechnology. 6 (2): 80–81. doi:10.1038/nnano.2011.4. PMID 21293484.
  34. ^ "Stealth Properties to Improve Therapeutic Efficacy of Drug Nanocarriers". Journal of Drug Delivery. 2013. 2013-03-07.
  35. ^ Hamad, I.; Hunter, A. C.; Szebeni, J.; Moghimi, S. M. (2008). "Poly(ethylene glycol)s generate complement activation products in human serum through increased alternative pathway turnover and a MASP-2-dependent process". Molecular Immunology. 46 (2): 225–232. doi:10.1016/j.molimm.2008.08.276. PMID 18849076.
  36. ^ "Suspicions grow that nanoparticles in Pfizer's COVID-19 vaccine trigger rare allergic reactions". Science.org. December 21, 2020.
  37. ^ Moghimi, S.M. (2014-09-28). "Cancer nanomedicine and the complement system activation paradigm: anaphylaxis and tumour growth". Journal of Controlled Release. 190: 556–562. doi:10.1016/j.jconrel.2014.03.051. PMID 24746624.
  38. ^ Wibroe, P. P.; Mat Azmi, I. D.; Nilsson, C.; Yaghmur, A.; Moghimi, S. M. (November 2015). "Citrem modulates internal nanostructure of glyceryl monooleate dispersions and bypasses complement activation: Towards development of safe tunable intravenous lipid nanocarriers". Nanomedicine: Nanotechnology, Biology, and Medicine. 11 (8): 1909–1914. doi:10.1016/j.nano.2015.08.003. PMID 26348655.
  39. ^ Wibroe, P. P.; Anselmo, A. C.; Nilsson, P. H.; Sarode, A.; Gupta, V.; Urbanics, R.; Szebeni, J.; Hunter, A. C.; Mitragotri, S.; Mollnes, T. E.; Moghimi, S. M. (2017). "Bypassing adverse injection reactions to nanoparticles through shape modification and attachment to erythrocytes". Nature Nanotechnology. 12 (6): 589–594. Bibcode:2017NatNa..12..589W. doi:10.1038/nnano.2017.47. hdl:10037/13642. PMID 28396605.
  40. ^ Moghimi, S. M. (2018). "Nanomedicine safety in preclinical and clinical development: focus on idiosyncratic injection/infusion reactions". Drug Discovery Today. 23 (5): 1034–1042. doi:10.1016/j.drudis.2017.11.006. PMID 29146517.
  41. ^ Wu, L. P.; Ficker, M.; Christensen, J. B.; Simberg, D.; Trohopoulos, P. N.; Moghimi, S. M. (2021-08-11). "Dendrimer end-terminal motif-dependent evasion of human complement and complement activation through IgM hitchhiking". Nature Communications. 12 (1): 4858. Bibcode:2021NatCo..12.4858W. doi:10.1038/s41467-021-24960-6. PMC 8357934. PMID 34381048.
  42. ^ Moghimi, S. M.; Simberg, D.; Anchordoquy TJ (2020). "Tuning the Engines of Nanomedicine". Molecular Therapy. 28 (3): 693–694. doi:10.1016/j.ymthe.2020.01.025. PMC 7054826. PMID 32032534.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Moein_Moghimi&oldid=1216139837"